A July 2026 press release from the U.S. Attorney’s Office for the Western District of Virginia detailed Scalpa CEO Bryce Cleveland’s guilty plea to three charges involving unapproved skincare products, including devices and the unapproved botulinum toxin product Scalpatox. Cleveland agreed to a prison term of four to eight years.
Federal Case Involves Unapproved Device and Botulinum Toxin Distribution
On July 31, 2026, the U.S. Attorney’s Office for the Western District of Virginia announced that Scalpa CEO Bryce Cleveland pleaded guilty to three counts in a federal case involving an unapproved botulinum toxin drug, Scalpatox, and unapproved device products sold to consumers between 2018 and 2020. For Med Spa and aesthetic operators, the case may provide compliance context on FDA product status and the marketing and distribution of drugs and devices used for cosmetic purposes.
Indictment Details Mail and Wire Fraud, Adulterated Devices, and an Unapproved New Drug
A July 24, 2024, federal indictment charged Cleveland with 34 counts in the Western District of Virginia. The U.S. Attorney’s Office reported that Cleveland pleaded guilty to 3 of those counts in July 2026 and agreed that he committed all 34 crimes charged in the indictment.
The indictment included the following charges:
- 12 counts of mail fraud involving products shipped from Arizona to locations in the Western District of Virginia between September 26, 2019, and September 13, 2020.
- 9 counts of wire fraud involving electronic communications between Scalpa and purchasers in the Western District of Virginia between September 26, 2019, and April 23, 2020.
- 12 counts involving the introduction of adulterated devices into interstate commerce between September 26, 2019, and September 13, 2020.
- 1 count involving the introduction of an unapproved new drug into interstate commerce on August 4, 2020.
The indictment identified several products involved in the alleged conduct:
- Fibroblast Pen: A device intended to discharge high-frequency electric current to the skin to improve appearance.
- Hyaluron Pen: A needle-free device intended to deliver hyaluronic acid serums and cross-linked gels into the skin.
- ScalpaJECT Hyaluronic Acid: A hyaluronic acid product intended for use as a dermal filler.
- Scalpatox: A drug containing Clostridium botulinum type A neurotoxin complex intended for injection to improve appearance.
The indictment states that the three Class III device products lacked FDA premarket approval or 510(k) clearance, and no approved New Drug Application or Abbreviated New Drug Application was in effect for Scalpatox. The indictment further alleged that Cleveland marketed unapproved devices while representing that they were not subject to FDA regulation. Under the July 2026 plea, Cleveland agreed to a prison term of four to eight years, restitution covering the scope of his criminal conduct, and $800,000 in forfeiture.
DISCOVER YOUR MED SPA’S GROWTH POTENTIAL
How much time and revenue could you unlock by outsourcing your GFEs?
Use our GFE Calculator to find out in under 5 minutes. It’s quick, easy, and tailored to your Med Spa.
Source: Federal Court Records and DOJ Press Release
According to a July 31, 2026, press release from the U.S. Attorney’s Office for the Western District of Virginia, Cleveland pleaded guilty to three federal charges involving mail fraud, an adulterated device, and an unapproved new drug. The July 24, 2024, grand jury indictment filed in the Western District of Virginia outlines the 34 counts, identifies the products and transactions involved, and details the alleged conduct and FDA status underlying the charges.
Compliance Considerations Involving Unapproved Drugs and FDA Class III Devices
The Federal Food, Drug, and Cosmetic Act (FDCA) provisions cited in the federal indictment address separate requirements for medical devices and new drugs entering interstate commerce. For the Class III devices, the indictment explains that applicable products could not be legally marketed without FDA premarket approval or, where applicable, 510(k) clearance. Cleveland was charged with introducing devices into interstate commerce that prosecutors alleged lacked either authorization.
The FDCA also addresses drug approval separately. A new drug generally may not be introduced into interstate commerce without an approved New Drug Application or Abbreviated New Drug Application. The indictment classified Scalpatox as a drug because it was intended to affect the structure and function of the human body. Count 34 identified it as an unapproved new drug with no FDA-approved application in effect.
For Med Spa and aesthetic operators, these distinctions make FDA status relevant when evaluating both injectable drugs and treatment devices. Product classification, intended use, injectable contents, labeling, and supplier representations can affect which FDA requirements apply. Similar federal actions involving imported peptide and GLP-1 products, and counterfeit Botox and dermal fillers provide additional examples of federal enforcement involving product approval, labeling, sourcing, and distribution.
The FDCA charges in the federal case involved separate requirements governing adulterated devices and an unapproved new drug introduced into interstate commerce.
Operational Implications for Med Spa Injectables and Treatment Devices
- Identify whether a product used in the practice is regulated by the FDA as a drug, device, or other applicable product type based on its intended use and function.
- Verify the manufacturer, supplier, and distribution source for injectable drugs and treatment devices using available purchasing and product records.
- Evaluate supplier documentation and claims regarding FDA approval, clearance, or other regulatory status.
- Review product labeling and intended use to confirm how a drug or device is represented and used within the practice.
- Maintain records supporting product identity, labeling, supplier information, and applicable FDA status for drugs and devices stocked or used in the practice.
What to Watch Next
As of this reporting, Cleveland has agreed to a four-to-eight-year prison term, restitution, and $800,000 in forfeiture. The U.S. Attorney’s Office also noted public health concerns involving unapproved and misbranded injectable products. Future FDA actions involving unapproved drugs, device authorization, and botulinum toxin products remain relevant for Med Spa, aesthetic, and wellness operators.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our website.
Image Attribution: “Courtroom, C. Bascom Slemp Federal Building, Big Stone Gap, Virginia” by Carol M. Highsmith, via Wikimedia Commons, public domain.
